|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/02/20 Wave Life Sciences Ltd. POS AM 2:1.1M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: POS AM Post-Effective Amendment of a Registration HTML 565K 2: EX-23.1 Consent of Experts or Counsel HTML 4K
| EX-23.1 |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Wave Life Sciences Ltd.:
We consent to the use of our reports dated March 2, 2020, with respect to the consolidated balance sheets of Wave Life Sciences Ltd. as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, Series A preferred shares and shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2019, incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
| This ‘POS AM’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/2/20 | 10-K, 8-K, POSASR | ||
| 12/31/19 | 10-K | |||
| 12/31/18 | 10-K, 10-K/A | |||
| List all Filings | ||||